^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Title:

lenvatinib (Lenvima) is accepted for use within NHS Scotland

Published date:
09/09/2016
Excerpt:
lenvatinib (Lenvima) is accepted for use within NHS Scotland...treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
Evidence Level:
Sensitive: A1 - Approval
Published date:
05/28/2015
Excerpt:
Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Papillary Thyroid Cancer: Consider systemic therapy…For progressive and/or symptomatic disease, consider lenvatinib (preferred) or sorafenib